OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Donanemab for Alzheimer’s Disease: A Systematic Review of Clinical Trials
Areeba Rashad, Atta Rasool, Muhammad Shaheryar, et al.
Healthcare (2022) Vol. 11, Iss. 1, pp. 32-32
Open Access | Times Cited: 36
Areeba Rashad, Atta Rasool, Muhammad Shaheryar, et al.
Healthcare (2022) Vol. 11, Iss. 1, pp. 32-32
Open Access | Times Cited: 36
Showing 1-25 of 36 citing articles:
Current and future therapeutic strategies for Alzheimer’s disease: an overview of drug development bottlenecks
Yong Peng, Hong Jin, Ya-hui Xue, et al.
Frontiers in Aging Neuroscience (2023) Vol. 15
Open Access | Times Cited: 62
Yong Peng, Hong Jin, Ya-hui Xue, et al.
Frontiers in Aging Neuroscience (2023) Vol. 15
Open Access | Times Cited: 62
Lecanemab (Leqembi) is not the right drug for patients with Alzheimer’s disease
Markku Kurkinen
Advances in Clinical and Experimental Medicine (2023) Vol. 32, Iss. 9, pp. 943-947
Open Access | Times Cited: 37
Markku Kurkinen
Advances in Clinical and Experimental Medicine (2023) Vol. 32, Iss. 9, pp. 943-947
Open Access | Times Cited: 37
Mesenchymal Stem Cell (MSC)-Based Drug Delivery into the Brain across the Blood–Brain Barrier
Toshihiko Tashima
Pharmaceutics (2024) Vol. 16, Iss. 2, pp. 289-289
Open Access | Times Cited: 13
Toshihiko Tashima
Pharmaceutics (2024) Vol. 16, Iss. 2, pp. 289-289
Open Access | Times Cited: 13
Digital Therapeutics for Improving Effectiveness of Pharmaceutical Drugs and Biological Products: Preclinical and Clinical Studies Supporting Development of Drug + Digital Combination Therapies for Chronic Diseases
Zack Biskupiak, Victor Vinh Ha, Aarushi Rohaj, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 2, pp. 403-403
Open Access | Times Cited: 11
Zack Biskupiak, Victor Vinh Ha, Aarushi Rohaj, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 2, pp. 403-403
Open Access | Times Cited: 11
Disease-Modifying Treatments and Their Future in Alzheimer’s Disease Management
Blake Smith, Raymond L. Ownby
Cureus (2024)
Open Access | Times Cited: 7
Blake Smith, Raymond L. Ownby
Cureus (2024)
Open Access | Times Cited: 7
Anti-amyloid: An antibody to cure Alzheimer’s or an attitude
Olivia M. Osborne, Oandy Naranjo, Bradlee L. Heckmann, et al.
iScience (2023) Vol. 26, Iss. 8, pp. 107461-107461
Open Access | Times Cited: 20
Olivia M. Osborne, Oandy Naranjo, Bradlee L. Heckmann, et al.
iScience (2023) Vol. 26, Iss. 8, pp. 107461-107461
Open Access | Times Cited: 20
Alzheimer’s Disease Immunotherapy: Current Strategies and Future Prospects
Ali Aljassabi, Tarek Zieneldien, Janice Kim, et al.
Journal of Alzheimer s Disease (2024) Vol. 98, Iss. 3, pp. 755-772
Closed Access | Times Cited: 6
Ali Aljassabi, Tarek Zieneldien, Janice Kim, et al.
Journal of Alzheimer s Disease (2024) Vol. 98, Iss. 3, pp. 755-772
Closed Access | Times Cited: 6
Alzheimer’s Disease as Type 3 Diabetes: Understanding the Link and Implications
Mateusz Kciuk, Weronika Kruczkowska, Julia Gałęziewska, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 22, pp. 11955-11955
Open Access | Times Cited: 5
Mateusz Kciuk, Weronika Kruczkowska, Julia Gałęziewska, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 22, pp. 11955-11955
Open Access | Times Cited: 5
Advances in the management of Alzheimer’s disease
Muhammad Shaheer Bin Faheem, Ahmed Ali Khan, M. Nawaz
Neurodegenerative Disease Management (2025), pp. 1-3
Closed Access
Muhammad Shaheer Bin Faheem, Ahmed Ali Khan, M. Nawaz
Neurodegenerative Disease Management (2025), pp. 1-3
Closed Access
Targeting Amyloid Pathology in Early Alzheimer’s: The Promise of Donanemab-Azbt
Nadia Khartabil, Ayda Awaness
Pharmacy (2025) Vol. 13, Iss. 1, pp. 23-23
Open Access
Nadia Khartabil, Ayda Awaness
Pharmacy (2025) Vol. 13, Iss. 1, pp. 23-23
Open Access
Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances
Qiu Jiang, Jie Liu, Shan Huang, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access
Qiu Jiang, Jie Liu, Shan Huang, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access
Nanoscale flow cytometry‐based quantification of blood‐based extracellular vesicle biomarkers distinguishes MCI and Alzheimer's disease
Thamara Dayarathna, Austyn D. Roseborough, Janice Gomes, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 9, pp. 6094-6106
Open Access | Times Cited: 4
Thamara Dayarathna, Austyn D. Roseborough, Janice Gomes, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 9, pp. 6094-6106
Open Access | Times Cited: 4
Alzheimer's disease: a comprehensive review of epidemiology, risk factors, symptoms diagnosis, management, caregiving, advanced treatments and associated challenges
Saeid Safiri, Amir Ghaffari Jolfayi, Asra Fazlollahi, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 4
Saeid Safiri, Amir Ghaffari Jolfayi, Asra Fazlollahi, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 4
Pathological and physiological functional cross-talks of α-synuclein and tau in the central nervous system
Mingyue Jin, Shengming Wang, Xiaodie Gao, et al.
Neural Regeneration Research (2023) Vol. 19, Iss. 4, pp. 855-862
Open Access | Times Cited: 10
Mingyue Jin, Shengming Wang, Xiaodie Gao, et al.
Neural Regeneration Research (2023) Vol. 19, Iss. 4, pp. 855-862
Open Access | Times Cited: 10
Donanemab: Not two without a third
Markku Kurkinen
Advances in Clinical and Experimental Medicine (2023) Vol. 32, Iss. 10, pp. 1085-1087
Open Access | Times Cited: 10
Markku Kurkinen
Advances in Clinical and Experimental Medicine (2023) Vol. 32, Iss. 10, pp. 1085-1087
Open Access | Times Cited: 10
Pharmacokinetic evaluation of donanemab for the treatment of Alzheimer’s
Tanya Song, Yunfei Wang, Bret Silverglate, et al.
Expert Opinion on Drug Metabolism & Toxicology (2024) Vol. 20, Iss. 6, pp. 411-417
Closed Access | Times Cited: 2
Tanya Song, Yunfei Wang, Bret Silverglate, et al.
Expert Opinion on Drug Metabolism & Toxicology (2024) Vol. 20, Iss. 6, pp. 411-417
Closed Access | Times Cited: 2
Amyloid dye pairs as spectral sensors for enhanced detection and differentiation of misfolded proteins
Anastasiia A. Stepanchuk, Peter K. Stys
Journal of Photochemistry and Photobiology B Biology (2023) Vol. 248, pp. 112786-112786
Closed Access | Times Cited: 5
Anastasiia A. Stepanchuk, Peter K. Stys
Journal of Photochemistry and Photobiology B Biology (2023) Vol. 248, pp. 112786-112786
Closed Access | Times Cited: 5
Longitudinal observational cohort study: Speech for Intelligent cognition change tracking and DEtection of Alzheimer’s Disease (SIDE-AD)
Stina Saunders, Fasih Haider, Craig Ritchie, et al.
BMJ Open (2024) Vol. 14, Iss. 3, pp. e082388-e082388
Open Access | Times Cited: 1
Stina Saunders, Fasih Haider, Craig Ritchie, et al.
BMJ Open (2024) Vol. 14, Iss. 3, pp. e082388-e082388
Open Access | Times Cited: 1
Passive Anti-Amyloid Beta Immunotherapies in Alzheimer’s Disease: From Mechanisms to Therapeutic Impact
Thomas Gabriel Schreiner, Cristina Croitoru, Diana Nicoleta Hodorog, et al.
Biomedicines (2024) Vol. 12, Iss. 5, pp. 1096-1096
Open Access | Times Cited: 1
Thomas Gabriel Schreiner, Cristina Croitoru, Diana Nicoleta Hodorog, et al.
Biomedicines (2024) Vol. 12, Iss. 5, pp. 1096-1096
Open Access | Times Cited: 1
Substance Delivery across the Blood-Brain Barrier or the Blood-Retinal Barrier Using Organic Cation Transporter Novel Type 2 (OCTN2)
Toshihiko Tashima
Future Pharmacology (2024) Vol. 4, Iss. 3, pp. 479-493
Open Access | Times Cited: 1
Toshihiko Tashima
Future Pharmacology (2024) Vol. 4, Iss. 3, pp. 479-493
Open Access | Times Cited: 1
A streamlined, resource-efficient immunoprecipitation-mass spectrometry method for quantifying plasma amyloid-β biomarkers in Alzheimer's disease
Thomas K. Karikari, Yijun Chen, Xuemei Zeng, et al.
Research Square (Research Square) (2024)
Open Access | Times Cited: 1
Thomas K. Karikari, Yijun Chen, Xuemei Zeng, et al.
Research Square (Research Square) (2024)
Open Access | Times Cited: 1
Discovery of an APP-Selective BACE1 Inhibitor for Alzheimer’s Disease
Jesus Campagna, Barbara Jagodzinska, Dongwook Wi, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 3
Jesus Campagna, Barbara Jagodzinska, Dongwook Wi, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 3
Carrier-Mediated Delivery of Low-Molecular-Weight N-Containing Drugs across the Blood–Brain Barrier or the Blood–Retinal Barrier Using the Proton-Coupled Organic Cation Antiporter
Toshihiko Tashima
Future Pharmacology (2023) Vol. 3, Iss. 4, pp. 742-762
Open Access | Times Cited: 3
Toshihiko Tashima
Future Pharmacology (2023) Vol. 3, Iss. 4, pp. 742-762
Open Access | Times Cited: 3
Dementia in Germany: epidemiology, trends and challenges.
Daniela Georges, Elena Rakuša, Anna-Victoria Holtz, et al.
PubMed (2023) Vol. 8, Iss. 3, pp. 30-48
Closed Access | Times Cited: 3
Daniela Georges, Elena Rakuša, Anna-Victoria Holtz, et al.
PubMed (2023) Vol. 8, Iss. 3, pp. 30-48
Closed Access | Times Cited: 3
The Neuropharmacological Evaluation of Seaweed: A Potential Therapeutic Source
Khoshnur Jannat, Rengasamy Balakrishnan, Jun‐Hyuk Han, et al.
Cells (2023) Vol. 12, Iss. 22, pp. 2652-2652
Open Access | Times Cited: 3
Khoshnur Jannat, Rengasamy Balakrishnan, Jun‐Hyuk Han, et al.
Cells (2023) Vol. 12, Iss. 22, pp. 2652-2652
Open Access | Times Cited: 3
